Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada’s owners improve offer

Executive Summary

Stada Arzneimittel’s controlling shareholders, Bain Capital and Cinven, have made an improved €81.83 (US$94.38) per share offer to minority shareholders as they seek to take full control of the German generics and OTC specialist. The offer is a tenth higher than the previous €74.40 per share bid that failed to attract holders of 35% of Stada shares not currently held by their Nidda Healthcare vehicle (Generics bulletin, 11 May 2018, page 6).

You may also be interested in...



Nidda Sets Price For Stada Squeeze-Out

Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has decided on a share price for the final squeeze-out of Stada’s remaining minority shareholders.

COVID-19: FDA Schedules More Virtual Town Halls For November And December

The US agency has announced four more webinars aimed at labs and manufacturers that are (or have) developed diagnostic tests for the novel coronavirus.

CBD Trademarks Remain Under Wraps In US As Brands Blanket Supplement Market

USPTO appeals board rejects requests by Charlotte's Web marketer in June and the Natural Leaf brand owner in September for trademarks. Those decisions sustain USPTO policy that even though FDA allows sales of food, supplements and other non-drug products subject to its oversight that contain hemp-derived CBD, the products are unlawful and trademarking brands for them is prohibited.

Topics

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel